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Neurofibromatosis Type 1 Protein and Amyloid
Precursor Protein Interact in Normal Human
Melanocytes and Colocalize with Melanosomes
Sofie De Schepper1,5, Joachim M.A. Boucneau1,5, Wendy Westbroek2, Mieke Mommaas3, Jos Onderwater3,
Ludwine Messiaen4, Jean-Marie A.D. Naeyaert1 and Jo L.W. Lambert1
The neurofibromatosis type 1 (NF1) gene product, neurofibromin, is known to interact with Ras, thereby
negatively regulating its growth-promoting function. Although this is a well-established interaction, the
discovery of other neurofibromin interacting partners could reveal new functional properties of this large
protein. Using yeast two-hybrid analysis against a brain cDNA library, we identified a novel interaction between
the amyloid precursor protein and the GTPase activating protein-related domain of neurofibromin. This
interaction was further analyzed in human melanocytes and confirmed by immunoprecipitation and
colocalization studies. In addition, we observed a colocalization of amyloid precursor protein and
neurofibromin with melanosomes. Amyloid precursor protein has been proposed to function as a vesicle
cargo receptor for the motor protein kinesin-1 in neurons. This colocalization of amyloid precursor protein and
neurofibromin with melanosomes was lost in melanocytes obtained from normal skin of a NF1 patient. We
suggest that a complex between amyloid precursor protein, neurofibromin, and melanosomes might be
important in melanosome transport, which could shed a new light on the etiopathogenesis of pigment-cell-
related manifestations in NF1.
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INTRODUCTION
Neurofibromatosis type 1 (NF1) is one of the most common
autosomal dominant neurocutaneous disorders in man with a
worldwide prevalence of roughly 1 in 3,500 individuals
(Riccardi, 1981). The disorder primarily affects tissues of
neural crest origin and exhibits a wide clinical expression
spectrum, ranging from benign peripheral nervous system
tumors (neurofibromas), optic pathway gliomas, skeletal
dysplasia to pigmentary defects (cafe´-au-lait spots, freckling,
Lisch nodules). Apart from the fact that the disease is a heavy
psychological burden, it is also accompanied by a number of
complications such as an increased risk of developing
malignancies and learning disabilities (De Schepper et al.,
2005). The disorder is caused by mutations of the NF1 gene.
This gene spans approximately 350 kb, is localized on
chromosome 17q11.2, and has 60 exons. The transcript is
11–13 kb long and encodes a protein, called neurofibromin,
of 2,818 amino acids (Viskochil et al., 1993). Neurofibromin
is a large protein expressed in numerous tissues with the
highest expression levels being observed in neurons
(Nordlund et al., 1993). The only region of neurofibromin,
which has been well characterized, is a central domain of
about 360 amino acids showing a significant sequence and
functional homology to the mammalian Ras-specific GTPase
activating proteins (RasGAPs – eg p120GAP). This domain is
called the GAP-related domain (GRD) and increases the slow
intrinsic GTPase activity of the growth regulator Ras up to
105-fold. A growing number of neurofibromin interacting or
associating proteins and organelles have been described over
the years. It has been shown that neurofibromin can bind to
certain major cytoskeletal structures. Neurofibromin is able
to associate with microtubules through its GRD and it has
been proposed that this association is important for regulating
the growth-promoting activity of Ras (Bollag et al., 1993;
Gregory et al., 1993; Xu and Gutmann, 1997). An interaction
switch between different cytoskeletal structures was descri-
bed in telencephalic neurons, with neurofibromin exhibiting
a biphasic differentiation-dependent expression pattern and a
differential subcellular localization to the F-actin and
microtubule cytoskeleton (Li et al., 2001). In addition, a
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stable association between the kinesin-1 heavy chain and
neurofibromin has recently been shown (Hakimi et al., 2002).
Interaction with extracellular matrix-binding proteins such as
the transmembrane heparan sulfate proteoglycan syndecan-2
has been suggested as a mechanism for localizing neuro-
fibromin to specific domains of the plasma membrane,
perhaps contributing to synaptic RasGAP activity or adhesion
signaling in the brain (Hsueh et al., 2001). Colocalization of
neurofibromin with the mitochondria in cultured cell lines
(Roudebush et al., 1997) has been described, whereas
localization to the smooth endoplasmic reticulum was seen
in neurons (Nordlund et al., 1993).
In order to find other functional interactions of neuro-
fibromin, we set up a yeast two-hybrid screening of the
neurofibromin-GRD and a brain cDNA library. In this report,
we demonstrate that b-amyloid precursor protein (APP)
interacts with the GRD of neurofibromin. We show that in
human melanocytes, neurofibromin and APP colocalize with
melanosomes. This interaction complex could be part of a
melanosome transport/biogenesis regulating mechanism or a
signaling complex or might be a mechanism for sequestering
neurofibromin from the plasma membrane, where it functions
as a negative regulator of Ras.
RESULTS
Identification of APP as a neurofibromin-binding protein
Screening of possible direct interactions of neurofibromin
with other proteins was performed using the GAL-4-based
yeast two-hybrid vector system. The GRD of neurofibromin
(bp 4,071–4,671) was screened against a commercially avail-
able brain cDNA library in the yeast strain Saccharomyces
cerevisiae PJ-69-4A.
One of the interactions that remained after stringent
selection with SD/-Leu-Trp-Ade, SD/-Leu-Trp-His, and the
X-gal filter assay was identified as APP. Because of its
important role in axonal transport in the brain (Kamal et al.,
2001) and its proposed role in melanosome transport and
melanin release (Quast et al., 2003), we decided to further
investigate this interaction.
To further confirm and investigate the neurofibromin–APP
interaction in human melanocytes, total melanocyte cell
lysate was incubated with NF1(D) antibody to immuno-
precipitate possible neurofibromin-containing protein com-
plexes. As shown in Figure 1a, several bands with molecular
masses between 70 and 200 kDa were obtained after silver
staining of the gel (p70, p110, p130, p150, p190), but none of
them were observed in the rabbit IgG isotype-matched
control. The observed proteins p110 and p130 match the
known molecular weights of immature (110 kDa) and mature
(130 kDa) APP. Using the anti-APP antibody (CT15), APP was
identified after Western blotting of a neurofibromin immu-
noprecipitate. The APP band, however, was located inter-
mediate between the immature and mature form of APP. The
reason for this remains unclear (Figure 1b, upper part). The
reverse experiment was also performed to see whether
neurofibromin co-immunoprecipitated with APP. This
showed a 250 kDa band corresponding to the neurofibromin
protein (Figure 1b, lower part).
Expression of APP and NF1 gene (product) in cultured primary
human epidermal melanocytes
We examined mRNA expression of APP and NF1 in normal
human melanocytes using primers APP-F and APP-R (Quast
et al., 2003) and NF1-F and NF1-R. We saw the appropriate
cDNA bands for the 751 and 770 isoforms of APP and for
NF1 (94 bp) (Figure 2a). In addition, we checked the protein
expression of APP using the polyclonal antiserum CT15 and
of neurofibromin using the NF1(D) in normal human
melanocytes by means of Western blot (Figure 2b). In human
melanocyte protein extract a clear band representing
neurofibromin was observed around 250 kDa. Two APP
isoforms of around 110 and 130 kDa were detected, being the
immature and mature isoforms of the protein, respectively.
Localization of APP and wild-type neurofibromin in cultured
primary human epidermal melanocytes (healthy donor) and
colocalization with melanosomes
As described earlier (Quast et al., 2003) APP is mainly
localized in a reticulum within the perinuclear region
showing colocalization with the endoplasmic reticulum and
premelanosomes and in granules at the tips of dendrites,
representing mature melanosomes.
We investigated the distribution of APP and neurofibromin
by indirect immunofluorescent labeling. In melanocytes, we
observed the previously reported perinuclear staining pattern
of APP associated with occasional staining of the dendrite tips
(Figure 3b). Neurofibromin showed a granular staining
pattern with perinuclear accentuation (Figure 3a).
Because both APP and neurofibromin displayed a similar
organellar punctate staining pattern, a double labeling of
neurofibromin and APP with the melanosomal marker NKI-
beteb was performed.
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Figure 1. Identification of neurofibromin interacting proteins. (a) Neuro-
fibromin in cell lysate of primary human epidermal melanocytes was
immunoprecipitated with NF1 sc-67 antibody and the immunoprecipitate
was analyzed by SDS-PAGE (6%) and silver stained. Lane C represents the
rabbit polyclonal IgG isotype matched control, lane IP represents the
neurofibromin immunoprecipitate. Molecular weight markers are shown on
the left and on the right black arrows indicate the position of immunopre-
cipitated protein bands (p70, p110, p130, p150, p190). (b) Upper right figure:
immunostaining with APP (CT15) antibody of NF1 sc-67 immunoprecipitate
(left lane) compared to the total cell lysate (right lane). Lower right figure:
immunoblotting with NF1 sc-67 antibody of APP (CT15) immunoprecipitate
(left lane) compared to the total cell lysate (right lane). Molecular weight
markers are shown in kDa.
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In melanocytes, NKI-beteb stains the melanocyte-specific
glycoprotein Pmel17 or gp100 and displays a punctate
staining pattern throughout the cell body and dendrites with
accentuation around the nucleus and in the dendrite tips. APP
shows a similar staining pattern especially around the
perinuclear area, which colocalizes with premelanosomes,
and in some of the dendrite tips, marking mature melano-
somes. The staining was less intense in the cell periphery.
Figure 3b shows high levels of colocalization between APP
and NKI-beteb. Neurofibromin shows a perinuclear staining
pattern with no obvious staining of the dendrite tips (Figure
3a). To study colocalization of neurofibromin and APP with
melanosomes on an ultra-structural level, immuno-electron
microscopy was performed. Figure 4a shows APP as 15 nm
gold particles situated on organelles resembling melano-
somes. Figure 4b shows neurofibromin as 15 nm gold
particles situated on melanosomes. To make sure that the
observed organelles are in fact melanosomes and not
lysosomes or other organelles, a double immunostaining of
neurofibromin (10 nm gold) and NKI-beteb (15 nm gold) was
performed (Figure 4d). The same was performed for APP
(Figure 4c). The results show remarkable colocalization on
melanosomes. Owing to technical limitations, we were not
able to perform double labelings of APP with neurofibromin.
An NF1 gene mutation deranges the colocalization of both APP
and neurofibromin with melanosomes
Double immunofluorescent staining was performed on
cultured NF1þ / primary human epidermal melanocytes
obtained from the skin of a severely affected NF1 patient with
a deletion of two nucleotides of the NF1 gene
(3,525_3,526del2). Figure 3c shows almost complete loss of
the overlap between neurofibromin and NKI-beteb, which
implicates that mutant neurofibromin is unable to colocalize
on melanosomes. Interestingly, Figure 3d indicates that this
NF1 gene deletion also affects the colocalization between
APP and melanosomes.
Ultrastrastructural study with immuno-electron micro-
scopy displayed less staining of neurofibromin (15 nm gold)
(Figure 4f). The observed decrease in neurofibromin expres-
sion can be explained by the haploinsufficiency of the NF1
gene locus due to NF1 heterozygosity. In the double
immunostainings of APP (15 nm gold) and NKI-beteb
(10 nm gold) (Figure 4 g), and neurofibromin (15 nm gold)
and NKI-beteb (10 nm gold) (Figure 4 h), a specific and clear
staining of melanosomes is visible. Neither APP nor neuro-
fibromin localize to melanosome structures nor to any other
identifiable structure.
DISCUSSION
Using yeast two-hybrid analysis against a brain cDNA library,
we found a direct binding of APP with the GRD of
neurofibromin. As our primary interest is in the pigment
cell-related manifestations in NF1, we further investigated the
APP–neurofibromin interaction in primary human epidermal
melanocytes.
APP is a type I transmembrane cell surface protein with a
large N-terminal extracellular part. Being known as the
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Figure 2. Expression of NF1 gene (product) and APP gene (product) in primary
human epidermal melanocytes. (a) Detection of NF1 (left) and APP (right)
mRNA expression by RT-PCR analysis in primary human epidermal melano-
cytes (obtained from two different donors (1 and 2)), displaying the expression
of both the 751 and 770 isoforms of APP. The same samples showed the
appropriate 94 bp band (arrow) when analyzed with the exon 36–37 NF1
boundary primers. (b) Expression of neurofibromin and APP proteins was
analyzed by SDS-PAGE (6%) followed by immunostaining with anti-neurofi-
bromin (NF1 sc-67) and anti-APP (CT15) antibodies. Molecular weight markers
are shown in kDa on the left. Note the immature and mature isoforms of APP.
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Figure 3. Subcellular distribution and localization of neurofibromin, APP
and melanosomes in healthy donor (NF1þ /þ ) and NF1 patient (NF1þ /)
primary human epidermal melanocytes. Healthy donor melanocytes were
cultured on coverslips for 24 hours, fixed and immunostained with (a) NKI-
beteb and neurofibromin and (b) NKI-beteb and APP. The overlay panels
show remarkable colocalization of neurofibromin especially in the peri-
nuclear area and of APP in the perinuclear area and the dendrite tips. NF1
patient melanocytes were cultured on coverslips for 24 hours, fixed and
immunostained with (c) NKI-beteb and neurofibromin and (d) NKI-beteb and
APP. A clear absence of colocalization can be seen. Bars¼10 mm.
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precursor of the amyloid-beta (Ab) peptides involved in the
pathogenesis of Alzheimer’s disease, APP consists of different
isoforms generated by alternative splicing of the APP gene.
APP isoforms 751 and 770 (numbers referring to their length
in amino acids) are found as the major translation products
in, among others, the epidermis, whereas isoform 695
(lacking exon 7 and 8) is most abundant in the brain (Quast
et al., 2003). APP expression is especially high in epidermal
melanocytes and therefore it has been suggested as an
immunocytochemical marker for this cell type (Quast et al.,
2003). b-Amyloid, a neurotoxic peptide, is generated from
APP through the action of b- and g-secretases. However, the
a-secretase pathway splits APP within the Ab domain,
producing a large amino-terminal non-amyloidogenic sAPPa,
which functions as a regulator of dendrite motility and
melanin release in epidermal melanocytes and melanoma
cells (Quast et al., 2003). Several interacting partners of APP
have been recently described. The Ab peptide binds to cyclin
B1 and increases human cyclin-dependent kinase-1 activity
(Milton, 2002). In addition, two-hybrid screening assays have
detected three proteins that interact with the specific
GYENPTY domain in the cytoplasmic tail of APP: Fe65,
X11, and mDab1 (mammalian homologue of Drosophila
disabled). Together with PAT1 (protein interacting with APP
tail 1), they may provide a link between APP and the
cytoskeleton (Herzog et al., 2004). APP also functions as a
matrix-binding protein interacting with perlecan, laminin,
collagen type IV and endactin, and as a copper-binding
protein important in neuronal copper homeostasis (Herzog
et al., 2004). Recent studies have demonstrated that the
C-terminal part of APP forms a complex with neuronal
kinesin-1 by direct binding to the tetratricopeptide repeat
domain of the kinesin light chain (Kamal et al., 2000) and that
the JNK signaling scaffold protein JIP1b mediates this
association (Inomata et al., 2003). Interestingly, neurofibro-
min has also been shown to interact with kinesin-1, with
cytoskeletal structures such as microtubules and with
extracellular matrix-binding proteins such as syndecan-2
(Hsueh et al., 2001; Li et al., 2001). The direct association
between neurofibromin and kinesin-1 was established by
conventional and affinity chromatography, Western blot, and
immunoprecipitation in the soluble and particulate fraction
of HeLa extract and calf brain (Hakimi et al., 2002). For the
first time, we show a direct interaction between APP and the
GRD of neurofibromin in the brain and in melanocytes,
which is not surprising considering that both are linked to
kinesin-1 and to the microtubular cytoskeleton and therefore
must exhibit a close spatial relationship. In addition, we
confirm the previously described colocalization of APP with
melanosomes (Quast et al., 2003) and show that neurofi-
bromin is also present on the melanosomal membrane and
forms a complex with APP. In neurons, APP is transported
from the neuronal cell bodies towards the distal nerve
terminals by kinesin-1-mediated axonal transport (Koo et al.,
1990; Sisodia et al., 1993). As has already been suggested in
a recent publication (Herzog et al., 2004), we also believe
that full-length APP aids the kinesin-mediated microtubular
transport of melanosomes along the dendrites.
The existence of a complex between APP, neurofibromin,
and melanosomes is especially interesting in light of the
many pigment-cell-related manifestations seen in NF1, with
cafe´-au-lait macules being the major hallmark. Our experi-
ments on NF1þ / melanocytes obtained from the skin of a
severely affected NF1 patient shows that the colocalization of
both APP and neurofibromin with melanosomes is disturbed
by the NF1 gene mutation (Figures 3c, d and 4e–h).
NF1 melanocytes, carrying an NF1 gene defect, contain
many large melanosomal complexes and increased amounts
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Figure 4. Ultrastructural distribution and localization of neurofibromin, APP and melanosomes in healthy donor (NF1þ /þ ) and NF1 patient (NF1þ /)
primary human epidermal melanocytes. Paraformaldehyde-fixed ultrathin cryosections of healthy donor primary human epidermal melanocytes were labeled
with (a) b-amyloid antibody (15 nm gold) and (b) neurofibromin antibody (15 nm gold). Both APP and neurofibromin showed melanosomal localization.
(c) A double labeling with NKI-beteb antibody (15 nm gold) and b-amyloid antibody (10 nm gold) revealed complexes associated on melanosomes (asterisk). The
plasmamembrane of the dendrite is marked with arrows. (d) A double labeling with NKI-beteb antibody (15 nm gold) and anti-neurofibromin (10 nm gold)
showed several melanosome-associated colocalization complexes (plus signs). Paraformaldehyde-fixed ultrathin cryosections of NF1 patient primary human
epidermal melanocytes were labeled with (e) APP antibody (15 nm gold) and (f) neurofibromin antibody (15 nm gold). No melanosomal localization was seen.
(g) The double labeling with NKI-beteb (10 nm gold) and APP (15 nm gold) and with (h) NKI-beteb (10 nm gold) and neurofibromin (15 nm gold) only showed
clear labeling of the melanosomal marker NKI-beteb but no colocalization of (g) APP or (h) neurofibromin. Bars¼ 500 nm.
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of melanin compared to normal human melanocytes
(Martuza et al., 1985; Kaufmann et al., 1991). Melanin
macroglobuli originate from the fusion of melanosome
complexes with phagolysosomes. They are aggregates of
melanosomes at various stages of melanization (De Schepper
et al., 2005). In this viewpoint, a mutated NF1 gene product
could, via the interaction with kinesin and APP, cause
problems in melanosome biogenesis or transport or could
even impair the interchange between melanosomes and
lysosomes, leading to macromelanosome formation.
In addition, an interesting notion considering NF1 and
Alzheimer’s disease (both being common neurological
disorders) is that neurofibromin and APP share their interac-
tion with the molecular motor protein kinesin-1. In neuronal
cells, processing of APP to b-amyloid can occur in an axonal
membrane compartment, containing b-secretase and pre-
senilin-1, transported by kinesin-1 (Kamal et al., 2000, 2001).
By demonstrating an interaction between neurofibromin and
APP and localizing both constituents to the melanosomes of
normal human melanocytes, we might expand the insight
into vesicular trafficking. In light of the frequent cognitive
defects in NF1 (mental retardation, learning disabilities, etc),
it could be that mutation of the NF1 gene product leads to an
impaired kinesin-1-mediated protein and vesicle trafficking
in neurons, perhaps distorting neurotransmitter transport or
synaptic RasGAP activity in the brain (Hsueh et al., 2001).
In summary, we provide new evidence for the existence of
a complex consisting of melanosomes, neurofibromin, and
APP, which might be relevant for the etiopathogenesis of
several symptoms found in NF1, such as pigmentation or
cognitive disorders.
MATERIALS AND METHODS
Cell culture
Primary human epidermal melanocyte cultures used for yeast two-
hybrid screening, co-immunoprecipitation, indirect immunofluores-
cence and immuno-electron microscopy were obtained from
neonatal foreskin of a healthy control individual or from an NF1
patient normal skin biopsy. Written informed consent was obtained
from all patients and all described protocols/studies were approved
by the medical ethical committee of the University of Ghent. The
study was conducted in accordance with institutional guidelines on
the Declaration of Helsinki Principles. Melanocyte cultures were
established as described previously (Naeyaert et al., 1991; Smit
et al., 1998). Briefly, the cells were cultured in Ham F10 (Gibco,
Invitrogen Ltd, Paisley, UK) medium supplemented with 2.5% fetal
calf serum, 1% Ultroser-G, 5 ng/ml basic fibroblast growth factor,
10 ng/ml endothelin-1, 0.33 nM cholera toxin, 5.3 nM D12-O-
tetradecanoylphorbol-13-acetate and 0.033 mM 3-isobutyl-1-methyl-
xanthine until subconfluency (80%).
Antibodies and reagents
Rabbit polyclonal antibodies NF1(D) (sc-67) (1/500) directed against
the C-terminus of neurofibromin and NF1(N) (sc-68) (1/500) directed
against the N-terminus were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Mouse monoclonal antibody NKI-beteb aimed
against the (pre)melanosomal silver protein was obtained from
Monosan (Uden, The Netherlands). Rabbit polyclonal antiserum
CT15 directed against the C-terminus of APP (1/500) was kindly
provided by Dr E. Koo (UCSD, San Diego, CA). Goat polyclonal
amyloid antibody (sc-5399) (Santa Cruz Biotechnology, Santa Cruz,
CA) was directed against the C-terminus and recommended for
detection of b-amyloid and amyloid A4. Secondary rabbit anti-
mouse and rabbit anti-goat immunoglobulins used for immuno-
electronmicroscopy were obtained from Dako (DakoCytomation,
Heverlee, Belgium). Horse radish peroxidase-conjugated anti-rabbit
IgG antibody (1/4,000) and HRP-conjugated anti-mouse IgG anti-
body (1/3,000) were from Amersham Biosciences (Orsay, France).
RT-PCR
Using the RNeasy method (Qiagen, Leusden, The Netherlands) total
RNA was extracted from normal human melanocytes. cDNA was
prepared from total RNA using random primers (Invitrogen Ltd,
Paisley, UK) and the Superscript II RT enzyme (Invitrogen Ltd,
Paisley, UK). PCR amplification reaction was performed using
normal human melanocyte cDNA, the Extaq enzyme (Takara Shuzo
Co, Otsy, Shiga, Japan) and primers APP-F 50-AAGCCACAGAGA
GAACCACCAGCATT-30 and APP-R 50-GCTTGACGTTCTGCCTCTT
CCCATT-30 (Quast et al., 2003) for APP and NF1-F 50-ACGAGTGTC
TCATGGGCAGAT-30 and NF1-R 50-ACTGTTGTAAGTGTCAGGTC
CTTTTAAG-30 for NF1. The thermal cycling conditions for APP were
30 cycles at 941C for 30 seconds, 551C for 30 seconds, and 721C for
45 seconds, and conditions for NF1 were 35 cycles at 951C for
30 seconds, 541C for 30 seconds, and 721C for 15 seconds. PCR
products were size-separated on a 2% agarose gel and visualized by
ethidium bromide staining.
Yeast two-hybrid analysis
Based on the full-length cDNA sequence of neurofibromin (GenBank
accession number: NM_000267), the region of interest was PCR
amplified using normal human melanocyte cDNA prepared from
total RNA. This region is referred to as ‘‘bait’’ (major part of the GRD:
bp 4,071–4,671). Primers used for amplification were baitF 50-ATC
AGTTCCTCCTCAGAATTC-30 and baitR 50-TACCTGATGCCTAGTCA
TAAA-30. The bait plasmid was constructed by directional insertion
of PCR product in the cloning site (EcoRI/SmaI) of the pBD-Gal 4
vector (Stratagene, La Jolla, CA).
As an additional positive control syndecan-2 (Genbank accession
number: XM_040582) was used (Hsueh et al., 2001). This plasmid
was constructed by BamHI-EcoRI directional cloning into the pAD-
Gal4-2.1 vector (Stratagene, La Jolla, CA) using the following
primers: SynF 50 GCGGAGTCGAGAGCAGAG-30 and SynR 50 TTAC
GCATAAAACTCCTTAGTAG-30. The inserts were sequence verified
by Baseclear (Leiden, The Netherlands). The human brain cDNA
library (‘‘prey’’) was inserted in the pAD-Gal4 vector. All constructs
were tested for auto-activation. Internal positive and negative
controls from Stratagene, being p53–pSV40 and pLamin–pSV40,
respectively, were used. Briefly, the NF1-GRD-pBD-Gal4 construct
and the commercial brain library construct (Clontech, BD Bios-
ciences, Palo Alto, CA) were sequentially transformed in the PJ-69-
4A yeast strain. Potential interactions were scored on selective
SD/-Leu-Trp-Ade, SD/-Leu-Trp-His growth medium and the b-galacto-
sidase filter assay. Only in cases where all three assays were positive,
yeast DNA was prepared for further analysis. After transformation of
the yeast DNA in supercompetent E. coli, the interacting proteins
were sequence verified by Baseclear (Leiden, The Netherlands).
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Immunoprecipitation
Normal human melanocytes were grown until subconfluency (80%)
in D12-O-tetradecanoylphorbol-13-acetate supplemented Ham F10
medium (Gibco, Invitrogen Ltd, Paisley, UK). After washing the cells
with dextrose supplemented phosphate-buffered saline, the cells
were lysed for 30 minutes at 41C with a mild lysis buffer (10 mM Tris,
150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.7% NP40,
pH 7.4), containing protease inhibitors (10 ml/ml phenylmethylsulfo-
nyl fluoride, 10 ml/ml Leupeptin, 10 ml/ml Aprotinin) and phospha-
tase inhibitors (20 ml/ml NaVO3, 50 ml/ml Na4P2O7, 10 ml/ml NaF
100 ). Insoluble cell material was pelleted by centrifugation at
14,000 r.p.m. at 41C for 10 minutes. The supernatant was collected
and protein concentration was determined with the DC Protein
Assay (BioRad, Hercules, CA). The supernatant was precleared with
25 ml protein A sepharose beads (Amersham Biosciences, Orsay,
France) under shaking for 30 minutes at 41C. After centrifugation,
immunoprecipitation was performed by incubating precleared
supernatant with either NF1(D) (sc-67) or APP antiserum CT15
under shaking for minimum 3 hours at 41C, followed by the addition
of 50ml protein A sepharose beads and incubation for 1 hour at 41C
under shaking. Unbound proteins were removed by extensive
washing. Immunoprecipitated proteins were extracted in 38 ml
1.5 Laemmli Sample Buffer and boiled for 5 minutes. The
immunoprecipitates were analyzed by Western blotting.
Western blotting
Immunoprecipitates or total cell lysate were solubilized and
denatured by boiling in 1.5 or 4 Laemmli sample buffer
respectively, containing 5% b-mercapto-ethanol and 0.25% bromo-
phenol blue. Proteins were separated by SDS-PAGE (6% gel) and
electro-blotted on to polyvinylidine diflouride membranes (Amer-
sham Biosciences, Orsay, France) or silver stained using the Silver
Stain Plus kit (Biorad, Hercules, CA). Membranes were blocked for
1 hour at room temperature in 5% non-fat dry milk in Tris buffered
saline with 0.1% Tween (137 mM NaCl, 20 mM Tris, pH 7.6 with
0.1% Tween-20), followed by incubation with the appropriate
primary antibody. Following several washing steps with Tris buffered
saline with 0.1% Tween, membranes were incubated with the
appropriate secondary antibody for 1 hour at room temperature.
After final washing steps with Tris buffered saline with 0.1% Tween,
bound antibodies were detected using the enhanced chemilumines-
cence detection system ECLþ Plus (Amersham Biosciences, Orsay,
France) according to the manufacturer’s protocol.
Indirect immunofluorescence and confocal microscopy
Melanocytes were grown on coverslips and fixed for 20 minutes at
room temperature with 3% paraformaldehyde in phosphate-buffered
saline. After three washes in tris-buffered saline, cells were
submerged for 10 minutes with 50 mM NH4Cl in phosphate-buffered
salineE (Eisen formulation) followed by three washes in tris-buffered
saline. For permeabilization, cells were treated for 5 minutes with
0.2% Triton X-100 in phosphate-buffered saline. Double staining for
neurofibromin and melanosomes was performed by first incubating
for 2 hours at room temperature in a 1/40 NKI-beteb and a 1/50
NF1(D) dilution. After three washes in tris-buffered saline, the
coverslips were incubated for 1 hour with an FITC-labeled rabbit
anti-mouse (1/20) and a biotinylated donkey anti-rabbit (1/50)
secondary antibody, respectively. Double staining for APP and
melanosomes was performed by first incubating for 2 hours at room
temperature in a 1/40 NKI-beteb and a 1/100 APP (CT15) dilution.
After three washes in tris-buffered saline, the coverslips were
incubated for 1 hour at room temperature in a biotinylated donkey
anti-rabbit (1/50) and a FITC-labeled rabbit anti-mouse (1/20)
antibody dilution. Slides were coverslipped in Prosan fluorescence
mounting fluid and confocal image (1mm) sections were obtained
with a BioRad Confocal Laser Scanning Microscope (Radiance 2100
blue laser diode).
Immunogold transmission electron microscopy
Melanocytes were fixed for 24 hours at room temperature in 2%
paraformaldehyde in 0.1 M PHEM buffer (60 mM Pipes/NaOH, 25 mM
Hepes, 10 mM EGTA and 2 mM MgSO4, pH 6.9–7.0) and processed
for immunogold labeling as described elsewhere (Mommaas et al.,
1992a, b). Briefly, cells were pelleted and embedded in 12% gelatin,
cut into 1 mmł cubes, cryoprotected in 2.3 M sucrose and snapfrozen
in liquid nitrogen. For localization of neurofibromin and APP,
ultrathin cryosections were incubated with the anti-neurofibromin
antibody NF1(D) diluted 1/500 or anti-goat b-amyloid/amyloid A4
(1/500) antibody (with intermediate rabbit-anti goat step) or anti-APP
(1/500) antibody (CT15), followed by 15 nm protein A-gold
incubation (1/200). For colocalization with melanosomes a double
labeling with the NKI-beteb antibody (dilution 1/300), after an
intermediate incubation step with a secondary rabbit anti-mouse
bridging antibody (1/200) and the NF1(D) (1/500) antibody was
performed. For double labeling with NKI-beteb and anti-goat
b-amyloid antibody, both an intermediate step with a secondary
rabbit anti-mouse (1/200) and rabbit anti-goat (1/200) antibody,
respectively, were necessary. All antibodies were incubated with 10
or 15 nm Protein A gold particles (1/200) for visualization. As
negative controls the primary antibodies were omitted, solely
including the secondary antibodies and 10 and 15 nm Protein A
gold particles. After immunolabeling, sections were embedded and
contrasted in methylcellulose/uranyl acetate and viewed with a
Philips EM 410 electron microscope (Eindhoven, The Netherlands).
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